Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial

Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial

Abstract Background Type 1 diabetes (T1D) places an extraordinary burden on individuals and their families, as well as on the healthcare system. Despite recent advances in glucose sensors and insulin pump technology, only a minority of patients meet their glucose targets and face the risk of both ac...

Full description

Bibliographic Details
Main Authors: M. Waibel, H. E. Thomas, J. M. Wentworth, J. J. Couper, R. J. MacIsaac, F. J. Cameron, M. So, B. Krishnamurthy, M. C. Doyle, T. W. Kay
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Trials
Subjects:
Type 1 diabetes
Baricitinib
Janus kinase (JAK) inhibitor
Insulin
C-peptide
Randomized controlled trial (RCT)
Online Access:https://doi.org/10.1186/s13063-022-06356-z

Internet

https://doi.org/10.1186/s13063-022-06356-z

Similar Items